Lupin Limited announced that Health Canada has approved Rymti, its biosimilar to Enbrel (etanercept), for use in Canada.
Rymti® is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
- Read more about Lupin Receives Health Canada Approval for Rymti (biosimilar Etanercept)
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/lupin-receives-health-canada-approval-for-rymti
No comments:
Post a Comment